BioNTech SE Equity-NMS: BNTX

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$160.35

52W high :

$388

1Y :

-55.79%

5Y :

879.1%

EPS(TTM): :

49.44

Shares O/S :

243.02 M

Market cap :

39.49 B

What is the share price of BioNTech SE today?

BioNTech SE (BNTX) share price as of August 15, 2022, is $162.48. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of BioNTech SE?

Yes, Indian Investors can invest in the BioNTech SE (BNTX) Share by opening an international trading account with Angel One.

How can I purchase BioNTech SE shares in India?

Purchasing BioNTech SE (BNTX) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying BioNTech SE (BNTX) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of BioNTech SE?

Yes, you can purchase fractional shares of BioNTech SE (BNTX) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of BioNTech SE?

The market capitalization of BioNTech SE on August 16, 2022, is $39.49 B.

In which sector BioNTech SE belongs?

BioNTech SE operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in BioNTech SE stocks?

In order to invest in BioNTech SE (BNTX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.